Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Background Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we d...

Full description

Bibliographic Details
Main Authors: Javier Martin-Broto, Paola Collini, Javier Martinez-Trufero, Antonio Lopez-Pousa, Lorenzo D'Ambrosio, Antonio Gutierrez, Herminia Perez-Vega, Victor Encinas-Tobajas, Enrique de Alava, Maria Peña-Chilet, Irene Carrasco-Garcia, Maria Lopez-Alvarez, David S Moura
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001561.full

Internet

https://jitc.bmj.com/content/8/2/e001561.full

Similar Items